Related Experiment Videos
Gas6, warfarin, and kidney diseases
1Yanagisawa Orphan Receptor Project, Exploratory Research for Advanced Technology, Japan Science and Technology Agency, National Museum of Emerging Science and Innovation, Tokyo, Japan. motoy@kuhp.kyoto-u.ac.jp
Clinical and Experimental Nephrology
|December 25, 2004
Summary
Growth arrest-specific gene 6 (Gas6) promotes kidney disease progression. Targeting the Gas6/Axl pathway with interventions like warfarin may prevent kidney disease development and progression.
Area of Science:
- Nephrology
- Molecular Biology
- Pharmacology
Background:
- Growth arrest-specific gene 6 (Gas6) is a vitamin K-dependent autocrine factor crucial for mesangial cell function.
- Warfarin, a vitamin K antagonist, inhibits mesangial cell proliferation by affecting Gas6 activation.
- The Gas6/Axl signaling pathway plays a significant role in various kidney diseases.
Purpose of the Study:
- To review the in vivo roles of Gas6 and its receptor Axl in kidney disease progression.
- To discuss potential therapeutic interventions targeting the Gas6/Axl pathway for kidney disease treatment.
Main Methods:
- Literature review of studies investigating Gas6 and Axl in kidney diseases.
- Analysis of the mechanism by which warfarin affects Gas6 activation and mesangial cell proliferation.
Main Results:
- Gas6 and Axl are implicated in the progression of acute and chronic glomerulonephritis.
- The Gas6/Axl pathway is involved in diabetic nephropathy and chronic allograft rejection.
- Studies highlight the role of Gas6/Axl in human kidney diseases.
Conclusions:
- The Gas6/Axl pathway is a key player in the pathogenesis of diverse kidney diseases.
- Targeting the Gas6/Axl pathway presents a promising therapeutic strategy for preventing kidney disease progression.